Dual Inhibitory Pathways of Metallofullerenol Gd@C 82 (OH) 22 on Matrix Metalloproteinase-2: Molecular insight into drug-like nanomedicine

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kang, Seung Gu ^a   Araya Secchi, Raul ^a   Wang, Deqiang ^a   Wang, Bo ^b   Huynh, Tien ^a   Zhou, Ruhong ^a,b,c  

^a IBM T J WATSON RESEARCH CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c Department of Chemistry Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FULLERENE DERIVATIVE; GADOLINIUM; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVE SITE; METABOLISM; MOLECULAR GENETICS; NANOMEDICINE; NEOPLASM; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BINDING SITES; CATALYTIC DOMAIN; FULLERENES; GADOLINIUM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NANOMEDICINE; NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 84899474485     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04775     Document Type: Article

References (50)

1. Wagner, V., Dullaart, A., Bock, A. K. & Zweck, A. The emerging nanomedicine landscape. Nat. Biotechnol. 24, 1211-1217 (2006
2. Schroeder, A. et al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 12, 39-50 (2012
3. Doane, T. L. & Burda, C. The unique role of nanoparticles in nanomedicine: Imaging, drug delivery and therapy. Chem. Soc. Rev. 41, 2885-2911 (2012
4. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug. Discov. 9, 615-627 (2010
5. Euliss, L. E., DuPont, J. A., Gratton, S. & DeSimone, J. Imparting size, shape, and composition control of materials for nanomedicine. Chem. Soc. Rev. 35, 1095-1104 (2006
6. Mout, R., Moyano, D. F., Rana, S. & Rotello, V. M. Surface functionalization of nanoparticles for nanomedicine. Chem. Soc. Rev. 41, 2539-2544 (2012
7. Yoo, D., Lee, J. H., Shin, T. H. & Cheon, J. Theranostic magnetic nanoparticles. Acc. Chem. Res. 44, 863-874 (2011
8. Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543-557 (2009
9. Lammers, T., Aime, S., Hennink, W. E., Storm, G. & Kiessling, F. Theranostic Nanomedicine. Acc. Chem. Res. 44, 1029-1038 (2011
10. Ge, C. et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 108, 16968-16973 (2011
11. Tu, Y. et al. Destructive extraction of phospholipids from Escherichia coli membranes by graphene nanosheets. Nat. Nanotechnol. 8, 594-601 (2013
12. Weinmann, H. J., Brasch, R. C., Press, W. R. & Wesbey, G. E. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. AM. J. Roentgenol. 142, 619-624 (1984
13. Brasch, R. C., Weinmann, H. J. & Wesbey, G. E. Contrast-enhanced NMR imaging: Animal studies using gadolinium-DTPA complex. AM. J. Roentgenol. 142, 625-630 (1984
14. Chen, C. et al.Multihydroxylated [Gd@C82(OH)22]n nanoparticles: Antineoplastic activity of high efficiency and low toxicity. Nano Lett. 5, 2050-2057 (2005
15. Kato, H. et al. Lanthanoid endohedral metallofullerenols for MRI contrast agents. J. Am. Chem. Soc. 125, 4391-4397 (2003
16. Liang, X. J. et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc. Natl. Acad. Sci. U.S.A. 107, 7449-7454 (2010
17. Meng, H. et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 4, 2773-2783 (2010
18. Kang, S. G. et al.Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C82(OH)22 and its implication for de novo design of nanomedicine Proc. Natl. Acad. Sci. U.S.A. 109, 15431-15436 (2012
19. Tallant, C.,Marrero, A. & Gomis-Ruth, F. X. Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim. Biophys. Acta. 1803, 20-28 (2010
20. Deryugina, E. I. & Quigley, J. P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta. 1803, 103-120 (2010
21. Nilsson, U. W. & Dabrosin, C. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res. 66, 4789-4794 (2006
22. Mott, J. D. &Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell. Biol. 16, 558-564 (2004
23. Kalluri, R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422-433 (2003
24. Heissig, B. et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109, 625-637 (2002
25. Jodele, S., Blavier, L., Yoon, J. M. & DeClerck, Y. A.Modifying the soil to affect the seed: Role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metast. Rev. 25, 35-43 (2006
26. Presta, M. et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16, 159-178 (2005
27. Jacobsen, J. A., Major Jourden, J. L., Miller, M. T. & Cohen, S. M. To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition. Biochim. Biophys. Acta. 1803, 72-94 (2010
28. Fang, Z., Grutter, C. & Rauh, D. Strategies for the selective regulation of kinases with allosteric modulators: Exploiting exclusive structural features. ACS Chem. Biol. 8, 58-70 (2013
29. Sawa, M. Strategies for the design of selective protein kinase inhibitors. Mini-Rev. Med. Chem. 8, 1291-1297 (2008
30. Cherry, M. &Williams, D. H. Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights. Curr. Med. Chem. 11, 663-673 (2004
31. Overall, C. M. & Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672 (2002
32. Yang, Z., Kang, S. G. & Zhou, R. Nanomedicine: De novo design of nanodrugs. Nanoscale 6, 663-677 (2013
33. Dhanaraj, V. et al. X-ray structure of gelatinase A catalytic domain complexed with a hydroxamate inhibitor. Croat. Chem. Acta 72, 575-591 (1999
34. Kang, S. G., Huynh, T. & Zhou, R. Non-destructive inhibition of metallofullerenol Gd@C82(OH)22) on WW domain: Implication on signal transduction pathway. Sci. Rep. 2, 957 (2012
35. Kang, S. G., Huynh, T. & Zhou, R. Metallofullerenol Gd@C82(OH)22 distracts the proline-rich-motif from putative binding on the SH3 domain. Nanoscale 5, 2703-2712 (2013
36. Yin, X. et al. Impacts of fullerene derivatives on regulating the structure and assembly of collagen molecules. Nanoscale 5, 7341-7348 (2013
37. Zuo, G.,Huang, Q.,Wei, G., Zhou, R.&Fang, H. Plugging into proteins: Poisoning protein function by a hydrophobic nanoparticle. ACS Nano 4, 7508-7514 (2010
38. Zuo, G., Zhou, X., Huang, Q., Fang, H. P. & Zhou, R. H. Adsorption of Villin Headpiece onto Graphene, Carbon Nanotube, and C60: Effect of Contacting Surface Curvatures on Binding Affinity. J. Phys. Chem. C 115, 23323-23328 (2011
39. Woolf, T. B., Grossfield, A. & Pearson, J. G. Indoles at interfaces: Calculations of electrostatic effects with density functional and molecular dynamics methods. Int. J. Quantum Chem. 75, 197-206 (1999
40. Wade, R. C., Gabdoulline, R. R., Ludemann, S. K. & Lounnas, V. Electrostatic steering and ionic tethering in enzyme-ligand binding: Insights from simulations. Proc. Natl. Acad. Sci. U.S.A. 95, 5942-5949 (1998
41. Zhou, R. Trp-cage: Folding free energy landscape in explicit water. Proc. Natl. Acad. Sci. U.S.A. 100, 13280-13285 (2003
42. Xu, X., Chen, Z., Wang, Y., Bonewald, L. & Steffensen, B. Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. Biochem. J. 406, 147-155 (2007
43. Martens, E. et al.Amonoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim. Biophys. Acta. 1770, 178-186 (2007
44. Yang, Z., Wang, Z., Tian, X., Xiu, P. & Zhou, R. Amino acid analogues bind to carbon nanotube via pi-pi interactions: Comparison of molecular mechanical and quantum mechanical calculations. J. Chem. Phys. 136, 025103 (2012
45. Overall, C. M. & Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94, 941-946 (2006
46. Engel, C. K. et al. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 12, 181-189 (2005
47. MacKerell, A. D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586-3616 (1998
48. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983
49. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An Nlog(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089-10092 (1993
50. Kumar, S. et al. Scalable molecular dynamics with NAMD on the IBM Blue Gene/L system. IBM J. Res. Develop. 52, 177-188 (2008).